Communiqués 4D Molecular Therapeutics, Inc.

Actions

FDMT

US35104E1001

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/09/2026			Varia. 5j.	Varia. 1 janv.
14,18 ^USD	-3,08%		-5,09%	+89,07%

13/08	4D Molecular Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
31/07	4D Molecular Therapeutics, Inc. : B. Riley toujours à l'achat	ZM

Communiqués

25/08	4DMT to Participate in Upcoming Investor Conferences	GL
25/08	4DMT to Participate in Upcoming Investor Conferences	AQ
14/08	4DMT Announces New Employment Inducement Grants	GL
13/08	4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones	GL
20/07	4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population	AQ
18/07	4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population	GL
17/07	4DMT Announces New Employment Inducement Grants	GL
30/06	4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists	GL
29/06	4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD	GL
29/06	4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD	AQ
29/06	4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital	GL
12/06	4DMT Announces New Employment Inducement Grants	GL
27/05	4DMT to Participate in Upcoming Investor Conferences	GL
18/05	4DMT Announces New Employment Inducement Grants	AQ
15/05	4DMT Announces New Employment Inducement Grants	GL
08/05	4D Molecular Therapeutics : 4DMT Corporate Presentation – May 2026 (b30118)	PU
08/05	4D Molecular Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones	GL
04/05	4DMT to Participate in Upcoming Investor Conferences	GL
04/05	4DMT to Participate in Upcoming Investor Conferences	AQ
17/04	4DMT Announces New Employment Inducement Grants	GL
18/03	4D Molecular Therapeutics : 4DMT Corporate Presentation – March 2026 (dfceb5)	PU
18/03	4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones	GL
16/03	4DMT to Participate in Upcoming Investor Meetings	GL
19/02	4DMT to Participate in Upcoming Investor Conferences	GL